Baroness Morgan of Drefelin
Labour - Life peer
Joined House of Lords: 11th June 2004
3 APPG Officer Positions (as of 12 Oct 2026)
Breast Cancer, Life Sciences, Stem Cell Transplantation and Advanced Cellular Therapies3 APPG Memberships
Carers, Diversity and Inclusion in Science, Technology, Engineering and Mathematics, Environment2 Former APPG Officer Positions
Cancer, Pancreatic CancerDivision Voting information
Debates during the 2024 Parliament
Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.
Sparring Partners
Parliamentary Under-Secretary (Department of Health and Social Care)
(10 debate interactions)
(4 debate interactions)
(2 debate interactions)
Department Debates
(14 debate contributions)
(4 debate contributions)
(2 debate contributions)
(2 debate contributions)
Legislation Debates
(744 words contributed)
(520 words contributed)
(347 words contributed)
(59 words contributed)
Lords initiatives
These initiatives were driven by Baroness Morgan of Drefelin, and are more likely to reflect personal policy preferences.
Baroness Morgan of Drefelin has not introduced any legislation before Parliament
Baroness Morgan of Drefelin has not co-sponsored any Bills in the current parliamentary sitting
Latest 10 Written Questions
(View all written questions)10 Department of Health and Social Care Questions
(View all Baroness Morgan of Drefelin's DHSC questions)The £1.55 billion investment in diagnostic capacity will support the return to National Health Service constitutional standards by increasing capacity across frontline services including elective care, cancer and urgent and emergency care. National demand and capacity modelling assessed the additional activity required to support the Referral to Treatment standard, enable the Faster Diagnosis Standard (FDS) for cancer to reach 80%, and meet demand from urgent and emergency care.
Funding is being rapidly committed and issued to providers following the appropriate governance, including business case and programme panel approvals. Spend is reported centrally each year, and the full £1.55 billion allocation is forecast to be spent by 31 March 2029. Funding is targeted at areas where diagnostic, elective and cancer performance is most challenged. The modelling included projected cancer referral trends to 2029/30 and the diagnostic capacity required to support the FDS. Delivery is monitored through DM01 diagnostic activity alongside FDS and 62-day cancer performance.
Of the £1.55 billion allocated for diagnostics across the Spending Review period, funding for digital diagnostics is split across 16 workstreams covering pathology, imaging and cross-cutting digital capabilities. Funding will be channelled through diagnostic networks, informed by regional digital roadmaps, with regional allocations confirmed once bids are approved. The investment is expected to increase diagnostic capacity and productivity through improved utilisation, reduced duplicate and low-value testing, greater interoperability and fewer unused appointment slots.
Parliamentary Under-Secretary (Department of Health and Social Care)
The £1.55 billion investment in diagnostic capacity will support the return to National Health Service constitutional standards by increasing capacity across frontline services including elective care, cancer and urgent and emergency care. National demand and capacity modelling assessed the additional activity required to support the Referral to Treatment standard, enable the Faster Diagnosis Standard (FDS) for cancer to reach 80%, and meet demand from urgent and emergency care.
Funding is being rapidly committed and issued to providers following the appropriate governance, including business case and programme panel approvals. Spend is reported centrally each year, and the full £1.55 billion allocation is forecast to be spent by 31 March 2029. Funding is targeted at areas where diagnostic, elective and cancer performance is most challenged. The modelling included projected cancer referral trends to 2029/30 and the diagnostic capacity required to support the FDS. Delivery is monitored through DM01 diagnostic activity alongside FDS and 62-day cancer performance.
Of the £1.55 billion allocated for diagnostics across the Spending Review period, funding for digital diagnostics is split across 16 workstreams covering pathology, imaging and cross-cutting digital capabilities. Funding will be channelled through diagnostic networks, informed by regional digital roadmaps, with regional allocations confirmed once bids are approved. The investment is expected to increase diagnostic capacity and productivity through improved utilisation, reduced duplicate and low-value testing, greater interoperability and fewer unused appointment slots.
Parliamentary Under-Secretary (Department of Health and Social Care)
The £1.55 billion investment in diagnostic capacity will support the return to National Health Service constitutional standards by increasing capacity across frontline services including elective care, cancer and urgent and emergency care. National demand and capacity modelling assessed the additional activity required to support the Referral to Treatment standard, enable the Faster Diagnosis Standard (FDS) for cancer to reach 80%, and meet demand from urgent and emergency care.
Funding is being rapidly committed and issued to providers following the appropriate governance, including business case and programme panel approvals. Spend is reported centrally each year, and the full £1.55 billion allocation is forecast to be spent by 31 March 2029. Funding is targeted at areas where diagnostic, elective and cancer performance is most challenged. The modelling included projected cancer referral trends to 2029/30 and the diagnostic capacity required to support the FDS. Delivery is monitored through DM01 diagnostic activity alongside FDS and 62-day cancer performance.
Of the £1.55 billion allocated for diagnostics across the Spending Review period, funding for digital diagnostics is split across 16 workstreams covering pathology, imaging and cross-cutting digital capabilities. Funding will be channelled through diagnostic networks, informed by regional digital roadmaps, with regional allocations confirmed once bids are approved. The investment is expected to increase diagnostic capacity and productivity through improved utilisation, reduced duplicate and low-value testing, greater interoperability and fewer unused appointment slots.
Parliamentary Under-Secretary (Department of Health and Social Care)
The £1.55 billion investment in diagnostic capacity will support the return to National Health Service constitutional standards by increasing capacity across frontline services including elective care, cancer and urgent and emergency care. National demand and capacity modelling assessed the additional activity required to support the Referral to Treatment standard, enable the Faster Diagnosis Standard (FDS) for cancer to reach 80%, and meet demand from urgent and emergency care.
Funding is being rapidly committed and issued to providers following the appropriate governance, including business case and programme panel approvals. Spend is reported centrally each year, and the full £1.55 billion allocation is forecast to be spent by 31 March 2029. Funding is targeted at areas where diagnostic, elective and cancer performance is most challenged. The modelling included projected cancer referral trends to 2029/30 and the diagnostic capacity required to support the FDS. Delivery is monitored through DM01 diagnostic activity alongside FDS and 62-day cancer performance.
Of the £1.55 billion allocated for diagnostics across the Spending Review period, funding for digital diagnostics is split across 16 workstreams covering pathology, imaging and cross-cutting digital capabilities. Funding will be channelled through diagnostic networks, informed by regional digital roadmaps, with regional allocations confirmed once bids are approved. The investment is expected to increase diagnostic capacity and productivity through improved utilisation, reduced duplicate and low-value testing, greater interoperability and fewer unused appointment slots.
Parliamentary Under-Secretary (Department of Health and Social Care)
The £1.55 billion investment in diagnostic capacity will support the return to National Health Service constitutional standards by increasing capacity across frontline services including elective care, cancer and urgent and emergency care. National demand and capacity modelling assessed the additional activity required to support the Referral to Treatment standard, enable the Faster Diagnosis Standard (FDS) for cancer to reach 80%, and meet demand from urgent and emergency care.
Funding is being rapidly committed and issued to providers following the appropriate governance, including business case and programme panel approvals. Spend is reported centrally each year, and the full £1.55 billion allocation is forecast to be spent by 31 March 2029. Funding is targeted at areas where diagnostic, elective and cancer performance is most challenged. The modelling included projected cancer referral trends to 2029/30 and the diagnostic capacity required to support the FDS. Delivery is monitored through DM01 diagnostic activity alongside FDS and 62-day cancer performance.
Of the £1.55 billion allocated for diagnostics across the Spending Review period, funding for digital diagnostics is split across 16 workstreams covering pathology, imaging and cross-cutting digital capabilities. Funding will be channelled through diagnostic networks, informed by regional digital roadmaps, with regional allocations confirmed once bids are approved. The investment is expected to increase diagnostic capacity and productivity through improved utilisation, reduced duplicate and low-value testing, greater interoperability and fewer unused appointment slots.
Parliamentary Under-Secretary (Department of Health and Social Care)
The latest reported survival outcomes for each of the 14 less common cancers referenced in the National Cancer Plan are currently available in the CONCORD-3 study with more up to date data being released in the CONCORD-4 study, which is due to be published by the London School of Hygiene and Tropical Medicine shortly. The Department will continue to use National Disease Registration Service published survival data to monitor progress on cancer survival in England and will ensure that we are improving outcomes across all tumour types.
We are committed to improving all outcomes, including for the 14 less common cancers referenced, as we continue to implement the commitments set out in the plan. Cancer waiting time performance and early diagnosis data provide good indications on where we are making progress and help to identify low-performing tumour types. Both of these datasets are available publicly.
The reformed National Cancer Board is the senior advisory body and governance structure responsible for tracking the progress of the commitments within the plan. The board will maintain momentum, provide challenge and scrutiny to areas of slow progress, and ensure that implementation translates into meaningful improvements for patients, including rare cancer patients. Dr Robert Metcalf has been appointed as the National Clinical Lead for Rare Cancers and will be responsible for providing independent challenge and supporting the delivery of the rare cancer commitments within the plan.
Parliamentary Under-Secretary (Department of Health and Social Care)
The latest reported survival outcomes for each of the 14 less common cancers referenced in the National Cancer Plan are currently available in the CONCORD-3 study with more up to date data being released in the CONCORD-4 study, which is due to be published by the London School of Hygiene and Tropical Medicine shortly. The Department will continue to use National Disease Registration Service published survival data to monitor progress on cancer survival in England and will ensure that we are improving outcomes across all tumour types.
We are committed to improving all outcomes, including for the 14 less common cancers referenced, as we continue to implement the commitments set out in the plan. Cancer waiting time performance and early diagnosis data provide good indications on where we are making progress and help to identify low-performing tumour types. Both of these datasets are available publicly.
The reformed National Cancer Board is the senior advisory body and governance structure responsible for tracking the progress of the commitments within the plan. The board will maintain momentum, provide challenge and scrutiny to areas of slow progress, and ensure that implementation translates into meaningful improvements for patients, including rare cancer patients. Dr Robert Metcalf has been appointed as the National Clinical Lead for Rare Cancers and will be responsible for providing independent challenge and supporting the delivery of the rare cancer commitments within the plan.
Parliamentary Under-Secretary (Department of Health and Social Care)
The latest reported survival outcomes for each of the 14 less common cancers referenced in the National Cancer Plan are currently available in the CONCORD-3 study with more up to date data being released in the CONCORD-4 study, which is due to be published by the London School of Hygiene and Tropical Medicine shortly. The Department will continue to use National Disease Registration Service published survival data to monitor progress on cancer survival in England and will ensure that we are improving outcomes across all tumour types.
We are committed to improving all outcomes, including for the 14 less common cancers referenced, as we continue to implement the commitments set out in the plan. Cancer waiting time performance and early diagnosis data provide good indications on where we are making progress and help to identify low-performing tumour types. Both of these datasets are available publicly.
The reformed National Cancer Board is the senior advisory body and governance structure responsible for tracking the progress of the commitments within the plan. The board will maintain momentum, provide challenge and scrutiny to areas of slow progress, and ensure that implementation translates into meaningful improvements for patients, including rare cancer patients. Dr Robert Metcalf has been appointed as the National Clinical Lead for Rare Cancers and will be responsible for providing independent challenge and supporting the delivery of the rare cancer commitments within the plan.
Parliamentary Under-Secretary (Department of Health and Social Care)
The latest reported survival outcomes for each of the 14 less common cancers referenced in the National Cancer Plan are currently available in the CONCORD-3 study with more up to date data being released in the CONCORD-4 study, which is due to be published by the London School of Hygiene and Tropical Medicine shortly. The Department will continue to use National Disease Registration Service published survival data to monitor progress on cancer survival in England and will ensure that we are improving outcomes across all tumour types.
We are committed to improving all outcomes, including for the 14 less common cancers referenced, as we continue to implement the commitments set out in the plan. Cancer waiting time performance and early diagnosis data provide good indications on where we are making progress and help to identify low-performing tumour types. Both of these datasets are available publicly.
The reformed National Cancer Board is the senior advisory body and governance structure responsible for tracking the progress of the commitments within the plan. The board will maintain momentum, provide challenge and scrutiny to areas of slow progress, and ensure that implementation translates into meaningful improvements for patients, including rare cancer patients. Dr Robert Metcalf has been appointed as the National Clinical Lead for Rare Cancers and will be responsible for providing independent challenge and supporting the delivery of the rare cancer commitments within the plan.
Parliamentary Under-Secretary (Department of Health and Social Care)